CN109071566B - 用于治疗癌症的大环mcl-1抑制剂 - Google Patents

用于治疗癌症的大环mcl-1抑制剂 Download PDF

Info

Publication number
CN109071566B
CN109071566B CN201780022366.0A CN201780022366A CN109071566B CN 109071566 B CN109071566 B CN 109071566B CN 201780022366 A CN201780022366 A CN 201780022366A CN 109071566 B CN109071566 B CN 109071566B
Authority
CN
China
Prior art keywords
compound
chloro
tetramethyl
oxa
tridecene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780022366.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN109071566A (zh
Inventor
A.赫德
M.A.贝尔蒙特
W.杨
J.P.塞克里斯特
D.W.罗宾斯
S.L.卡斯米尔斯基
D.吴
B.彭
J.约翰斯
M.L.兰布
Q.叶
郑晓兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN109071566A publication Critical patent/CN109071566A/zh
Application granted granted Critical
Publication of CN109071566B publication Critical patent/CN109071566B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D497/00Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/22Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D515/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780022366.0A 2016-04-22 2017-04-21 用于治疗癌症的大环mcl-1抑制剂 Active CN109071566B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662326156P 2016-04-22 2016-04-22
US62/326156 2016-04-22
PCT/EP2017/059511 WO2017182625A1 (en) 2016-04-22 2017-04-21 Macrocyclic mcl1 inhibitors for treating cancer

Publications (2)

Publication Number Publication Date
CN109071566A CN109071566A (zh) 2018-12-21
CN109071566B true CN109071566B (zh) 2021-08-31

Family

ID=58664658

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780022366.0A Active CN109071566B (zh) 2016-04-22 2017-04-21 用于治疗癌症的大环mcl-1抑制剂

Country Status (37)

Country Link
US (4) US9840518B2 (enExample)
EP (1) EP3445767B1 (enExample)
JP (1) JP6894449B2 (enExample)
KR (1) KR102388208B1 (enExample)
CN (1) CN109071566B (enExample)
AR (1) AR108301A1 (enExample)
AU (1) AU2017252222B2 (enExample)
BR (1) BR112018070677B1 (enExample)
CL (1) CL2018002410A1 (enExample)
CO (1) CO2018008759A2 (enExample)
CR (1) CR20180499A (enExample)
CY (1) CY1123186T1 (enExample)
DK (1) DK3445767T3 (enExample)
DO (1) DOP2018000222A (enExample)
EA (1) EA036551B1 (enExample)
ES (1) ES2791319T3 (enExample)
HR (1) HRP20200673T1 (enExample)
HU (1) HUE049591T2 (enExample)
IL (1) IL262237B (enExample)
LT (1) LT3445767T (enExample)
MA (1) MA44721B1 (enExample)
ME (1) ME03729B (enExample)
MX (1) MX386103B (enExample)
NI (1) NI201800093A (enExample)
PE (1) PE20181803A1 (enExample)
PH (1) PH12018502227A1 (enExample)
PL (1) PL3445767T3 (enExample)
PT (1) PT3445767T (enExample)
RS (1) RS60257B1 (enExample)
SG (1) SG11201805838UA (enExample)
SI (1) SI3445767T1 (enExample)
SM (1) SMT202000249T1 (enExample)
SV (1) SV2018005742A (enExample)
TN (1) TN2018000319A1 (enExample)
TW (1) TWI742074B (enExample)
WO (1) WO2017182625A1 (enExample)
ZA (1) ZA201807766B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11066416B2 (en) 2016-02-04 2021-07-20 The Johns Hopkins University Rapafucin derivative compounds and methods of use thereof
EP3411046B1 (en) 2016-02-04 2025-07-16 The Johns Hopkins University Rapaglutins, novel inhibitors of glut and use thereof
WO2017136717A1 (en) 2016-02-04 2017-08-10 The Johns Hopkins University Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof
ME03729B (me) 2016-04-22 2021-01-20 Astrazeneca Ab Makrociklički mcl1 inhibitor! za tretman raka
US10981932B2 (en) 2016-05-19 2021-04-20 Bayer Aktiengesellschaft Macrocyclic indole derivatives
TWI781996B (zh) * 2017-03-31 2022-11-01 瑞典商阿斯特捷利康公司 合成mcl-1抑制劑之方法
TW201904976A (zh) * 2017-03-31 2019-02-01 瑞典商阿斯特捷利康公司 Mcl-1抑制劑及其使用方法
EP3652184A4 (en) 2017-08-15 2020-05-20 AbbVie Inc. MACROCYCLIC INHIBITORS OF MCL-1 AND METHODS OF USE
CA3073113A1 (en) * 2017-08-15 2019-02-21 Abbvie Inc. Macrocyclic mcl-1 inhibitors and methods of use
WO2019096907A1 (en) * 2017-11-17 2019-05-23 Bayer Aktiengesellschaft Aryl annulated macrocyclic indole derivatives
EP3710450A1 (en) * 2017-11-17 2020-09-23 Bayer Aktiengesellschaft Macrocyclic chlorine substituted indole derivatives
AR113886A1 (es) 2017-11-17 2020-06-24 Broad Inst Inc Derivados de indol macrocíclicos
WO2019096905A1 (en) * 2017-11-17 2019-05-23 Bayer Aktiengesellschaft Macrocyclic chlorine substituted indole derivatives
EP3710449B1 (en) 2017-11-17 2022-07-06 The Broad Institute, Inc. Macrocyclic fluorine substituted indole derivatives as mcl-1 inhibitors, for use in the treatment of cancer
JP7234250B2 (ja) * 2017-11-17 2023-03-07 バイエル アクチェンゲゼルシャフト 置換大環状インドール誘導体
TW202014184A (zh) 2018-04-30 2020-04-16 瑞典商阿斯特捷利康公司 用於治療癌症之組合
EP3858840A4 (en) * 2018-09-30 2022-05-04 Jiangsu Hengrui Medicine Co., Ltd. INDOL MACROCYCLIC DERIVATIVE, METHOD OF PRODUCTION THEREOF AND APPLICATION THEREOF IN MEDICINE
TW202344250A (zh) 2018-11-14 2023-11-16 瑞典商阿斯特捷利康公司 治療癌症之方法
CN111205309B (zh) * 2018-11-21 2023-04-07 江苏恒瑞医药股份有限公司 吲哚类大环衍生物、其制备方法及其在医药上的应用
CN110845520B (zh) * 2018-11-22 2021-04-13 苏州亚盛药业有限公司 作为mcl-1抑制剂的大环吲哚
CN112204036B (zh) 2019-01-23 2022-12-27 苏州亚盛药业有限公司 作为mcl-1抑制剂的大环稠合的吡唑
CA3131939A1 (en) * 2019-03-08 2020-09-17 Zeno Management, Inc. Macrocyclic compounds
CN113574058B (zh) * 2019-04-30 2024-04-16 江苏恒瑞医药股份有限公司 吲哚类大环衍生物、其制备方法及其在医药上的应用
BR112021022237A2 (pt) 2019-05-10 2022-03-29 Janssen Biotech Inc Queladores macrocíclicos e métodos de uso dos mesmos
WO2020236556A1 (en) 2019-05-17 2020-11-26 The Broad Institute, Inc. Methods of preparing macrocyclic indoles
US20230092679A1 (en) 2019-05-20 2023-03-23 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
BR112021025732A2 (pt) 2019-06-21 2022-04-12 Janssen Pharmaceutica Nv Inibidores macrocíclicos de mcl-1
ES2987630T3 (es) 2019-07-09 2024-11-15 Janssen Pharmaceutica Nv Derivados de espirociclos macrocíclicos como inhibidores de MCL-1
WO2021067405A1 (en) * 2019-10-01 2021-04-08 The Johns Hopkins University Neuroprotective compounds and methods of use thereof
WO2021092053A1 (en) * 2019-11-08 2021-05-14 Unity Biotechnology, Inc. Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
WO2021092061A1 (en) * 2019-11-08 2021-05-14 Unity Biotechnology, Inc. Combination treatment for senescence-associated diseases
EP4061819A1 (en) 2019-11-21 2022-09-28 Janssen Pharmaceutica NV Macrocyclic indole derivatives as mcl-1 inhibitors
WO2021099580A1 (en) 2019-11-21 2021-05-27 Janssen Pharmaceutica Nv Macrocyclic sulfonyl derivatives as mcl-1 inhibitors
BR112022012136A2 (pt) * 2019-12-18 2022-08-30 Zeno Man Inc Compostos macrocíclicos
WO2021165370A1 (en) 2020-02-21 2021-08-26 Janssen Pharmaceutica Nv Macrocyclic indole derivatives as inhibitors of mcl-1
TW202144368A (zh) * 2020-03-30 2021-12-01 大陸商江蘇恒瑞醫藥股份有限公司 吲哚類大環衍生物的結晶形式及其製備方法
JP2023526985A (ja) * 2020-05-29 2023-06-26 ヤンセン ファーマシューティカ エヌ.ベー. Mcl-1の阻害剤としての大環状7-ピラゾール-5-イル-インドール誘導体
US20230234965A1 (en) 2020-06-19 2023-07-27 Janssen Pharmaceutica Nv N-linked macrocyclic 4-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1
US20230234969A1 (en) 2020-06-19 2023-07-27 Janssen Pharmaceutica Nv N-linked macrocyclic 7-(pyrazol-5-yl)-indole derivatives as inhibiors of mcl-1
CN115776888A (zh) 2020-07-08 2023-03-10 詹森药业有限公司 含大环醚的吲哚衍生物作为mcl-1抑制剂
WO2022032284A1 (en) * 2020-08-07 2022-02-10 Zeno Management, Inc. Macrocyclic compounds
US20240042051A1 (en) 2020-11-24 2024-02-08 Francesca Rocchetti Mcl-1 inhibitor antibody-drug conjugates and methods of use
CN116710458A (zh) 2020-12-17 2023-09-05 詹森药业有限公司 作为mcl-1抑制剂的支链大环4-(吡唑-5-基)-吲哚衍生物
CN116848126A (zh) 2021-02-12 2023-10-03 詹森药业有限公司 大环1,3-桥联的6-氯-7-吡唑-4-基-1h-吲哚-2-羧酸酯和6-氯-7-嘧啶-5-基-1h-吲哚-2-羧酸酯衍生物作为mcl-1抑制剂用于治疗癌症
WO2022251247A1 (en) * 2021-05-28 2022-12-01 Zeno Management, Inc. Macrocyclic compounds
WO2022261310A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-body drug conjugates
EP4351564A1 (en) 2021-06-11 2024-04-17 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
CN115490708B (zh) * 2021-06-18 2025-01-24 苏州亚盛药业有限公司 磺酰胺类大环衍生物及其制备方法和用途
WO2023057484A1 (en) 2021-10-06 2023-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy
WO2023225359A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
WO2025111450A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd74 antibody-drug conjugates and methods of use thereof
WO2025111431A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd7 antibody-drug conjugates and methods of use thereof
WO2025126157A1 (en) 2023-12-15 2025-06-19 Advesya Anti-il-1rap binding domains and antibody-drug conjugates thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009011210A (es) 2007-04-16 2009-10-30 Abbott Lab Inhibidores de mcl1 de indol 7-no sustituido.
JP5496877B2 (ja) * 2007-04-16 2014-05-21 アッヴィ・インコーポレイテッド 7−置換インドールMcl−1阻害薬
EP2674437A1 (en) * 2008-12-22 2013-12-18 Cubist Pharmaceuticals, Inc. Novel antibacterial agents for the treatment of GRAM positive infections
KR20120098908A (ko) * 2009-12-23 2012-09-05 아이언우드 파마슈티컬스, 인코포레이티드 Crth2 조절제
RU2598840C2 (ru) * 2011-05-19 2016-09-27 Фундасион Сентро Насиональ Де Инвестигасионес Онколохикас Карлос Iii Новые соединения
WO2014047427A2 (en) 2012-09-21 2014-03-27 Vanderbilt University Substituted benzofuran, benzothiophene and indole mcl-1 inhibitors
EP3038618B1 (en) 2013-08-28 2020-10-14 Vanderbilt University Substituted indole mcl-1 inhibitors
US9944656B2 (en) * 2014-02-12 2018-04-17 VIIV Healthcare UK (No.5) Limited Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication
JP6757312B2 (ja) 2014-03-27 2020-09-16 ヴァンダービルト ユニバーシティー 置換インドールmcl−1阻害剤
CU24399B1 (es) * 2014-04-11 2019-04-04 Bayer Pharma AG Nuevos compuestos macrocíclicos en calidad de inhibidores de cdk9, un proceso para su preparación y los compuestos intermediarios útiles en la preparación de estos compuestos
US9949965B2 (en) 2014-10-17 2018-04-24 Vanderbilt University Tricyclic indole Mcl-1 inhibitors and uses thereof
ME03729B (me) 2016-04-22 2021-01-20 Astrazeneca Ab Makrociklički mcl1 inhibitor! za tretman raka

Also Published As

Publication number Publication date
NZ748173A (en) 2025-05-02
PH12018502227A1 (en) 2019-07-29
SV2018005742A (es) 2019-03-25
HUE049591T2 (hu) 2020-09-28
EP3445767A1 (en) 2019-02-27
TN2018000319A1 (en) 2020-01-16
MX2018012711A (es) 2019-05-30
US11472816B2 (en) 2022-10-18
EA036551B1 (ru) 2020-11-23
CA3020378A1 (en) 2017-10-26
IL262237A (en) 2018-11-29
ZA201807766B (en) 2021-09-29
JP6894449B2 (ja) 2021-06-30
KR20180135030A (ko) 2018-12-19
MA44721A (fr) 2019-02-27
AU2017252222A1 (en) 2018-11-29
EA201892300A1 (ru) 2019-05-31
DOP2018000222A (es) 2018-10-31
PT3445767T (pt) 2020-05-13
NI201800093A (es) 2019-03-14
BR112018070677A2 (pt) 2019-02-05
IL262237B (en) 2021-08-31
CL2018002410A1 (es) 2018-12-07
WO2017182625A1 (en) 2017-10-26
TW201803879A (zh) 2018-02-01
EP3445767B1 (en) 2020-02-19
DK3445767T3 (da) 2020-05-18
JP2019514863A (ja) 2019-06-06
US20210230184A1 (en) 2021-07-29
CY1123186T1 (el) 2021-10-29
CO2018008759A2 (es) 2018-09-20
ME03729B (me) 2021-01-20
US20190185485A1 (en) 2019-06-20
US10196404B2 (en) 2019-02-05
PL3445767T3 (pl) 2020-07-13
US9840518B2 (en) 2017-12-12
TWI742074B (zh) 2021-10-11
ES2791319T3 (es) 2020-11-03
MX386103B (es) 2025-03-18
AU2017252222B2 (en) 2019-11-07
US20180155362A1 (en) 2018-06-07
BR112018070677B1 (pt) 2024-02-06
LT3445767T (lt) 2020-05-25
CR20180499A (es) 2019-01-25
RS60257B1 (sr) 2020-06-30
MA44721B1 (fr) 2020-05-29
KR102388208B1 (ko) 2022-04-18
PE20181803A1 (es) 2018-11-19
SI3445767T1 (sl) 2020-07-31
AR108301A1 (es) 2018-08-08
SG11201805838UA (en) 2018-11-29
US20170305926A1 (en) 2017-10-26
HRP20200673T1 (hr) 2020-07-10
SMT202000249T1 (it) 2020-07-08
CN109071566A (zh) 2018-12-21
US10889594B2 (en) 2021-01-12

Similar Documents

Publication Publication Date Title
CN109071566B (zh) 用于治疗癌症的大环mcl-1抑制剂
CN109071534B (zh) 布罗莫结构域抑制剂
TW201904976A (zh) Mcl-1抑制劑及其使用方法
KR102544033B1 (ko) 치료용 덴드리머
RS62781B1 (sr) Policiklični amidni derivati kao inhibitori cdk9
WO2016173505A1 (en) Certain protein kinase inhibitor
WO2017114351A1 (en) Certain protein kinase inhibitors
WO2017133663A1 (en) Phosphorus containing compounds as protein kinase inhibitors
CN109890792A (zh) 布罗莫结构域抑制剂
CA3020378C (en) Macrocyclic mcl1 inhibitors for treating cancer
HK1260481A1 (en) Macrocyclic mcl1 inhibitors for treating cancer
HK1260481B (zh) 用於治疗癌症的大环mcl-1抑制剂
HK1262770A1 (en) Macrocyclic mcl1 inhibitors for treating cancer
HK1262770B (en) Macrocyclic mcl1 inhibitors for treating cancer
HK40002495A (en) Bromodomain inhibitors
HK40002495B (zh) 布罗莫结构域抑制剂
BR112017027394B1 (pt) Composto, forma cristalina, composição farmacêutica e uso do mesmo

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1260481

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant